ACHV PE Ratio & Valuation,Is ACHV Overvalued

ACHV Relative Valuation

ACHV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACHV is overvalued; if below, it's undervalued.

Historical Valuation

Achieve Life Sciences Inc (ACHV) is now in the Fair zone, suggesting that its current forward PS ratio of 50.72 is considered Fairly compared with the five-year average of -2.87. The fair price of Achieve Life Sciences Inc (ACHV) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：5.47

Fair

-4.23

0.00

EV/EBITDA

Achieve Life Sciences Inc. (ACHV) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.28. The thresholds are as follows: Strongly Undervalued below -1.43, Undervalued between -1.43 and -0.86, Fairly Valued between 0.30 and -0.86, Overvalued between 0.30 and 0.87, and Strongly Overvalued above 0.87. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.65

EV/EBIT

Achieve Life Sciences Inc. (ACHV) has a current EV/EBIT of -3.65. The 5-year average EV/EBIT is -2.02. The thresholds are as follows: Strongly Undervalued below -4.17, Undervalued between -4.17 and -3.09, Fairly Valued between -0.94 and -3.09, Overvalued between -0.94 and 0.14, and Strongly Overvalued above 0.14. The current Forward EV/EBIT of -3.65 falls within the Undervalued range.

50.72

Achieve Life Sciences Inc. (ACHV) has a current PS of 50.72. The 5-year average PS is 188.09. The thresholds are as follows: Strongly Undervalued below -937.70, Undervalued between -937.70 and -374.80, Fairly Valued between 750.99 and -374.80, Overvalued between 750.99 and 1313.88, and Strongly Overvalued above 1313.88. The current Forward PS of 50.72 falls within the Historic Trend Line -Fairly Valued range.

-4.53

P/OCF

Achieve Life Sciences Inc. (ACHV) has a current P/OCF of -4.53. The 5-year average P/OCF is -2.00. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and -3.62, Fairly Valued between -0.37 and -3.62, Overvalued between -0.37 and 1.25, and Strongly Overvalued above 1.25. The current Forward P/OCF of -4.53 falls within the Undervalued range.

-4.22

P/FCF

Achieve Life Sciences Inc. (ACHV) has a current P/FCF of -4.22. The 5-year average P/FCF is -2.29. The thresholds are as follows: Strongly Undervalued below -5.74, Undervalued between -5.74 and -4.01, Fairly Valued between -0.56 and -4.01, Overvalued between -0.56 and 1.17, and Strongly Overvalued above 1.17. The current Forward P/FCF of -4.22 falls within the Undervalued range.

Achieve Life Sciences Inc (ACHV) has a current Price-to-Book (P/B) ratio of 7.81. Compared to its 3-year average P/B ratio of 24.98 , the current P/B ratio is approximately -68.74% higher. Relative to its 5-year average P/B ratio of 17.00, the current P/B ratio is about -54.07% higher. Achieve Life Sciences Inc (ACHV) has a Forward Free Cash Flow (FCF) yield of approximately -15.37%. Compared to its 3-year average FCF yield of -26.24%, the current FCF yield is approximately -41.41% lower. Relative to its 5-year average FCF yield of -35.48% , the current FCF yield is about -56.66% lower.

7.81

P/B

Median3y

24.98

Median5y

17.00

-15.37

FCF Yield

Median3y

-26.24

Median5y

-35.48

Competitors Valuation Multiple

The average P/S ratio for ACHV's competitors is 8.73, providing a benchmark for relative valuation. Achieve Life Sciences Inc Corp (ACHV) exhibits a P/S ratio of 50.72, which is 481.16% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ACHV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ACHV in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Achieve Life Sciences Inc (ACHV) currently overvalued or undervalued?

What is Achieve Life Sciences Inc (ACHV) fair value?

ACHV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Achieve Life Sciences Inc (ACHV) is between to according to relative valuation methord.

How does ACHV's valuation metrics compare to the industry average?

What is the current P/B ratio for Achieve Life Sciences Inc (ACHV) as of Jan 08 2026?

As of Jan 08 2026, Achieve Life Sciences Inc (ACHV) has a P/B ratio of 7.81. This indicates that the market values ACHV at 7.81 times its book value.

What is the current FCF Yield for Achieve Life Sciences Inc (ACHV) as of Jan 08 2026?

As of Jan 08 2026, Achieve Life Sciences Inc (ACHV) has a FCF Yield of -15.37%. This means that for every dollar of Achieve Life Sciences Inc’s market capitalization, the company generates -15.37 cents in free cash flow.

What is the current Forward P/E ratio for Achieve Life Sciences Inc (ACHV) as of Jan 08 2026?

As of Jan 08 2026, Achieve Life Sciences Inc (ACHV) has a Forward P/E ratio of -4.23. This means the market is willing to pay $-4.23 for every dollar of Achieve Life Sciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Achieve Life Sciences Inc (ACHV) as of Jan 08 2026?

As of Jan 08 2026, Achieve Life Sciences Inc (ACHV) has a Forward P/S ratio of 50.72. This means the market is valuing ACHV at $50.72 for every dollar of expected revenue over the next 12 months.

ACHV Valuation